In 2004, Bevacizumab, an anti-VEGF-A, was the first human anti-angiogenic antibody approved for the treatment of colorectal cancer (CRC), and then approved in various diseases such as breast cancer (BC), non-small cell lung cancer (NSCLC), ovarian cancer (OC), and renal cell carcinoma (RCC) [3]. Here, VEGFA is linked to renal cell carcinoma.